Last reviewed · How we verify

NCT05088161

Prognostic Biomarkers of Pancreatic Cancer Based on Proteomics Techniques

Status unknown Last updated 21 October 2021
What this trial tests

trial in Patients in 20 participants. Status unknown.

Timeline
13 May 2021
Primary endpoint
12 November 2021
12 March 2022

Quick facts

Lead sponsorThe Affiliated Hospital of Qingdao University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment20
Start date13 May 2021
Primary completion12 November 2021
Estimated completion12 March 2022
Sites1 location across China

Conditions studied

Sponsor

The Affiliated Hospital of Qingdao University

Who can join

Eligibility, any sex, with Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, we will use high-throughput proteomics techniques to search for biomarkers of post-operative prognosis of pancreatic cancer in samples of patients who have been diagnosed with pancreatic cancer through bioinformatics analysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Patients

Currently open trials in the same condition.

Other The Affiliated Hospital of Qingdao University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05088161.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing